6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Drug resistance frequently results in poor prognosis and high 5-year recurrence rate in estrogen receptor-negative (ER-) breast cancer patients. Herein, we examined the reversal effects of fulvestrant on multidrug resistance (MDR) in ER- breast cancer cells. Co-administration of fulvestrant significantly sensitized ER- MDR tumors to paclitaxel both in vitro and in vivo. Further analyses indicated that fulvestrant did not affect P-gp expression, but could inhibit P-gp function and subsequently reverse P-gp mediated drug resistance in ER- breast cancer cells. These results showed that combination of fulvestrant and chemotherapeutic agents might provide an effective treatment for ER- MDR breast cancers.

          Related collections

          Author and article information

          Journal
          Cancer Lett.
          Cancer letters
          Elsevier BV
          1872-7980
          0304-3835
          May 01 2014
          : 346
          : 2
          Affiliations
          [1 ] Program of Innovative Cancer Therapeutics, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
          [2 ] Program of Innovative Cancer Therapeutics, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
          [3 ] Department of Biological Sciences, National University of Singapore, Singapore.
          [4 ] Program of Innovative Cancer Therapeutics, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, USA. Electronic address: fanw@musc.edu.
          Article
          S0304-3835(14)00034-2
          10.1016/j.canlet.2014.01.008
          24462822
          3ace3bf1-cfcc-4672-b15f-221de0f331c0
          History

          Breast cancer,Drug resistance,Estrogen receptor,Fulvestrant,Paclitaxel

          Comments

          Comment on this article